



## Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference

March 2, 2026

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET.

A live webcast of the Company's presentation will be available under the "News & Events" tab in the Investor Calendar section of the Company's website at <https://ir.galecto.com/news-and-events/events>. An archived replay will be accessible for 30 days following the event.

### About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto's pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto's pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.

#### Media Contact:

Lia Dangelico  
Deerfield Group  
[lia.dangelico@deerfieldgroup.com](mailto:lia.dangelico@deerfieldgroup.com)

#### Investor Contact:

Brian Ritchie  
LifeSci Advisors  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)



Source: Galecto, Inc.